Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


CNS Pharmaceuticals, Inc. (CNSP) Create: Alert

All | News | Filings
Date FiledTypeDescription
07/22/2020 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
06/29/2020 GN Life Sciences Companies Investor Presentations Now Available for On-Demand Viewing
06/25/2020 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "CNS Pharmaceuticals, Inc. Investor Presentation – June 2020"
06/16/2020 4 Keyes Jeffry R. (Director) has filed a Form 4 on CNS Pharmaceuticals, Inc.
Txns: Granted 46,559 options to buy @ $2.47, valued at $115k
06/16/2020 4 Gumulka Jerzy (Director) has filed a Form 4 on CNS Pharmaceuticals, Inc.
Txns: Granted 46,559 options to buy @ $2.47, valued at $115k
06/16/2020 4 Evans Carl Anthony (Director) has filed a Form 4 on CNS Pharmaceuticals, Inc.
Txns: Granted 46,559 options to buy @ $2.47, valued at $115k
06/16/2020 4 Andraczke Andrzej (Director) has filed a Form 4 on CNS Pharmaceuticals, Inc.
Txns: Granted 46,559 options to buy @ $2.47, valued at $115k
06/11/2020 8-K Other Events, Financial Statements and Exhibits
Docs: "The Ruth Group 646-536-7028 / 7032 [email protected] [email protected] Kirsten Thomas The Ruth Group 280-6592"
06/09/2020 8-K Submission of Matters to a Vote of Security Holders
05/28/2020 8-K Other Events, Financial Statements and Exhibits
Docs: "The Ruth Group 646-536-7028 / 7032 [email protected] [email protected] Kirsten Thomas The Ruth Group 280-6592"
05/27/2020 8-K Other Events, Financial Statements and Exhibits
Docs: "The Ruth Group 646-536-7028 / 7032 [email protected] [email protected] Kirsten Thomas The Ruth Group 280-6592"
05/18/2020 8-K Other Events, Financial Statements and Exhibits
Docs: "The Ruth Group 646-536-7028 / 7032 [email protected] [email protected] Kirsten Thomas The Ruth Group 280-6592"
05/15/2020 10-Q Quarterly Report for the period ended March 31, 2020
04/24/2020 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/24/2020 C-TR Form C-TR - Termination of Reporting:
03/26/2020 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Development Agreement between CNS Pharmaceuticals, Inc. and WPD Pharmaceuticals"
03/12/2020 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "CNS Pharmaceuticals, Inc. Statements of Operations Year Ended Dec. 31, 2019 Year Ended Dec. 31, 2018 3 Mon. Ended Dec. 31, 2019 3 Mon. Ended Dec. 31, 2018 Operating expenses: General and administrative $ 1,978,643 $ 860,520 $ 1,039,337 $ 208,583 Research and development 1,854,334 21,267 1,484,394 – Total operating expenses 3,832,977 881,787 2,523,731 208,583 Loss from operations Other expense: Loss on settlement of liabilities – – Loss on change in fair value of SAFE agreements – – SAFE agreement expenses – – – Interest expense Amortization of debt discount – Total other expense Net loss $ $ $ Loss per share - basic and diluted $ $ $ $ Weighted average shares outstanding - basic and diluted 13,647,908 10,510,551 15,072,760 10,536,004 4 CNS Pharmaceuticals, Inc. Balance Sheets"
03/12/2020 10-K Annual Report for the period ended December 31, 2019
03/10/2020 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "CNS Pharmaceuticals, Inc. Investor Presentation – March 2020"
03/02/2020 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "CNS Pharmaceuticals, Inc. Investor Presentation – March 2020"
01/16/2020 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "CNS Pharmaceuticals Licenses DNA-Binding Agent from MD Anderson, Doubling its Drug Pipeline"
01/16/2020 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "CNS Pharmaceuticals, Inc. Investor Presentation – January 2020"
01/13/2020 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "CNS Pharmaceuticals, Inc. Investor Presentation – January 2020"
12/20/2019 10-Q Quarterly Report for the period ended September 30, 2019
11/22/2019 8-K Quarterly results
11/13/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "CNS Pharmaceuticals Announces Closing Of Initial Public Offering of Common Stock"
11/13/2019 4 Form 4 - Statement of changes in beneficial ownership of securities:
11/13/2019 3 Form 3 - Initial statement of beneficial ownership of securities:
11/08/2019 3 Priebe Waldemar (10% Owner) has filed a Form 3 on CNS Pharmaceuticals, Inc.
11/08/2019 3 Keyes Jeffry R. (Director) has filed a Form 3 on CNS Pharmaceuticals, Inc.
11/08/2019 3 Gumulka Jerzy (Director) has filed a Form 3 on CNS Pharmaceuticals, Inc.
11/08/2019 3 Evans Carl Anthony (Director) has filed a Form 3 on CNS Pharmaceuticals, Inc.
11/08/2019 3 Climaco John M (CEO) has filed a Form 3 on CNS Pharmaceuticals, Inc.
11/08/2019 3 Andraczke Andrzej (Director) has filed a Form 3 on CNS Pharmaceuticals, Inc.
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy